Izraelis - anglų - Ministry of Health

astrazeneca (israel) ltd - metformin hydrochloride; saxagliptin - film coated tablets - extended release - saxagliptin 2.5 mg; metformin hydrochloride 1000 mg - metformin - kombiglyze xr is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.

Izraelis - anglų - Ministry of Health

unipharm trading ltd, israel - pegfilgrastim - solution for injection - pegfilgrastim 10 mg/ml - pegfilgrastim - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy, given at intervals of 14 days or more, for malignancy. (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).

Izraelis - anglų - Ministry of Health

teva israel ltd - caffeine; chlorpheniramine maleate; paracetamol; phenylephrine hydrochloride - caplets - paracetamol 300 mg; chlorpheniramine maleate 2 mg; phenylephrine hydrochloride 10 mg; caffeine 30 mg - phenylephrine, combinations - phenylephrine, combinations - symptomatic relief of common cold, congestion associated with sinusitis, allergic rhinitis accompanied by fever and pain.

Izraelis - anglų - Ministry of Health

reckitt benckiser (near east) ltd - alginic acid as sodium; calcium carbonate; sodium bicarbonate - suspension - alginic acid as sodium 50 mg/ml; sodium bicarbonate 26.7 mg/ml; calcium carbonate 16 mg/ml - alginic acid - salt solutions - gastro reflux, heartburn, flatulence associated with gastric reflux, heartburn of pregnancy, all cases of epigastric and retrosternal distress where the underlying cause is gastric reflux.

Airija - anglų - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - clobazam - oral suspension - 1 milligram(s)/millilitre - benzodiazepine derivatives; clobazam - anxiolytics - it is indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, perizam must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. perizam may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.

Airija - anglų - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - clobazam - oral suspension - 2 milligram(s)/millilitre - benzodiazepine derivatives; clobazam - anxiolytics - it is a 1,5-benzodiazepine indicated in adults for the short-term symptomatic treatment (2-4 weeks) only of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. in treatment of anxiety states associated with affected disorders, perizam must only be used in conjunction with adequate treatments for the underlying disorder. in patients with schizophrenic or other psychotic illnesses, use of benzodiazepines is recommended only for short term symptomatic management of hyperarousal and agitation. benzodiazepines do not possess antipsychotic properties. perizam may be used as adjunctive therapy in epilepsy in adults or children over 6, if standard treatment with one or more anticonvulsants has failed.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine), quantity: 1 mg - injection, solution - excipient ingredients: tartaric acid; sodium metabisulfite; sodium chloride; water for injections - the drug of choice in the emergency treatment of acute severe anaphylactic reactions due to insect bites, drugs and other allergens. it may also be used for the symptomatic relief of respiratory distress due to bronchospasm.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alprazolam, quantity: 2 mg - tablet, uncoated - excipient ingredients: docusate sodium; sodium starch glycollate; povidone; maize starch; sodium benzoate; lactose monohydrate; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica - anxiety. short-term symptomatic treatment of anxiety including treatment of anxious patients with some symptoms of depression. panic disorder. the treatment of panic disorder with or without some phobic avoidance, and for blocking or attenuation of panic attacks and phobias in patients who have agoraphobia with panic attacks. the diagnostic criteria for panic disorder in dsm-iii-r are as follows: the panic attacks (discrete periods of intense fear or discomfort), at least initially, are unexpected. later in the course of this disturbance, certain situations (eg. driving a car or being in a crowded place) may become associated with having a panic attack. these panic attacks are not triggered by situations in which the person is the focus of others' attention (as in social phobia). the diagnosis requires four such attacks within a four week period, or one or more attacks followed by at least a month of persistent fear of having another attack. the panic attacks must be characterised by at least four of the following symptoms: dyspnoea or smothering sensations; dizziness, unsteady feelings or faintness; palpitations or tachycardia; trembling or shaking; sweating; choking; nausea or abdominal distress; depersonalisation or derealisation; paraesthesiae; flushes (hot flashes) or chills; chest pain or discomfort; fear of dying; fear of going crazy or of doing something uncontrolled. note: attacks involving four or more symptoms are panic attacks; attacks involving fewer than four are limited symptom attacks. at least some of the panic attack symptoms must develop suddenly and increase in intensity within ten minutes of the beginning of the first symptom noticed in the attack. the panic attack must not be attributable to some known organic factor, eg. amphetamine or caffeine, intoxication, hyper-thyroidism. the efficacy of alprazolam in conditions where the above criteria are not met has not been established. the risk versus benefits of alprazolam use in milder disorders, which do not meet the above criteria, has not been evaluated. although current evidence supports the long-term clinical effectiveness of alprazolam in panic disorder, the continuing use of alprazolam needs to be weighed against the difficulties that can occur with dependence and discontinuation. the results of a long-term study in patients taking alprazolam (ie. beyond three months) suggest that many patients continue to benefit from alprazolam therapy and that alprazolam efficacy is maintained for up to eight months. the physician should periodically reassess the usefulness of the drug for each patient. a comparative study of alprazolam and placebo in the treatment of panic attacks in patients with panic disorder involved 543 patients over an eight week period. alprazolam was significantly more effective than placebo in reducing the total number of panic attacks (p<0.0001); at week 4, 46.8% of alprazolam patients had achieved zero total panic attacks when compared to 27.1% of placebo patients. panic disorders are often severe, chronic illnesses that cause a high level of work and social disability, increased substance abuse and potentially increased morbidity and mortality. psychological and social factors are important in the pathogenesis of panic attacks, either acting alone or in combination with biological factors. prolonged pharmacological therapy may be used as an adjunct to psychosocial therapy in the treatment of patients with panic disorders.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

samsung bioepis au pty ltd - trastuzumab, quantity: 150 mg - injection, powder for - excipient ingredients: histidine hydrochloride monohydrate; histidine; trehalose dihydrate; polysorbate 20; water for injections - ontruzant is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy. ontruzant is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant ontruzant. ontruzant is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a. as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; b. in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c. in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer. ontruzant is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2-positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

maxx pharma pty ltd - trastuzumab, quantity: 150 mg - powder - excipient ingredients: histidine; sorbitol; histidine hydrochloride monohydrate; macrogol 3350; sodium hydroxide; hydrochloric acid - ? early breast cancer,ogivri is indicated for the treatment of her2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.,? locally advanced breast cancer,ogivri is indicated for the treatment of her2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant ogivri.,? metastatic breast cancer,ogivri is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2:,a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;,b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or,c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.,? advanced gastric cancer,ogivri is indicated in combination with cisplatin and either capecitabine or 5-fu for the treatment of patients with her2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.